Rehan Verjee, Director at Tyra Biosciences, Inc. (TYRA), bought 971 shares at $20.58 ($20K) on 2026-09-09, disclosed to the SEC on 2026-09-11.
Director Rehan Verjee purchased $20,000 of TYRA stock at $20.58, marking the largest insider purchase in the company's history, potentially signaling confidence despite recent volatility. This move comes as the stock has been hammered by negative clinical trial data, presenting a potential contrarian entry point for sophisticated traders.
TYRA has crashed 17.5% over the last five days and is down 6.9% over the past month, trading at $23.54. The stock is currently 42.09% below its 52-week high of $40.65 and has lost 12.62% of its value over the last 90 days.
1) Q3 2026 earnings on September 30, 2026; 2) Upcoming conference call on September 9, 2026, to discuss Phase 2 SURF302 trial results; 3) The company is pursuing its own approach to treating bladder cancer alongside Johnson & Johnson.
1) The stock is down 30% in a single day following mixed Phase 2 trial results for dabogratinib; 2) The company faces significant competition from Johnson & Johnson in the bladder cancer space.
Something here stands out, but not much.